Bauer, Todd M. http://orcid.org/0000-0002-3078-5043
Moore, Kathleen N. http://orcid.org/0000-0002-5803-0718
Rader, Janet S. http://orcid.org/0000-0001-7031-3385
Simpkins, Fiona http://orcid.org/0000-0002-0840-2368
Mita, Alain C.
Beck, J. Thaddeus http://orcid.org/0000-0002-3341-9903
Hart, Lowell
Chu, Quincy
Oza, Amit
Tinker, Anna V. http://orcid.org/0000-0002-1190-7746
Imedio, Esteban Rodrigo http://orcid.org/0000-0001-5666-666X
Kumar, Sanjeev
Mugundu, Ganesh http://orcid.org/0000-0002-3736-1884
Jenkins, Suzanne http://orcid.org/0000-0003-2435-1836
Chmielecki, Juliann
Jones, Suzanne http://orcid.org/0000-0001-6881-8050
Spigel, David http://orcid.org/0000-0003-3215-9465
Fu, Siqing http://orcid.org/0000-0002-1933-0419
Clinical trials referenced in this document:
Documents that mention this clinical trial
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors
https://doi.org/10.1007/s11523-023-00965-7
Funding for this research was provided by:
AstraZeneca
Article History
Accepted: 27 March 2023
First Online: 6 June 2023
Declarations
:
: The study was funded by AstraZeneca, which participated in the following: design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
: <i>T.M. Bauer</i> has received fees for consulting or advisory roles for Guardant Health, Ignyta (Inst), Loxo, Moderna Therapeutics (Inst), and Pfizer. <i>K. Moore</i> has received fees for advisory boards from AstraZeneca, Aravive, Clovis, Immunogen, Genentech/Roche, GSK/Tesaro, Mersana, Vavotar, Samumed, Mereo, Merck, Pfizer, Janssen, Oncomed, and VBL Therapeutics and is a principal investigator for investigator-initiated clinical trials funded by AstraZeneca and Immunogen. <i>F. Simpkins</i> has participated in advisory boards for AstraZeneca and is a principal investigator for an investigator-initiated clinical trial funded by AstraZeneca. <i>J.T. Beck</i> has received grant funding from AstraZeneca, Bristol-Myers Squibb, Lilly, Novartis, Genentech, AbbVie, Seattle Genetics, Pfizer, and Johnson & Johnson. <i>Q. Chu</i> has received honoraria (unrelated to adavosertib) from and participated in advisory boards for AstraZeneca. <i>A. Oza</i> has participated in advisory boards for AstraZeneca, GlaxoSmithKline, Tesaro, and Clovis and is a principal investigator and has participated in steering committees for clinical trials funded by AstraZeneca. <i>A.V. Tinker</i> has received research funding and honoraria from AstraZeneca and has participated in advisory boards and received honoraria from GlaxoSmithKline. <i>S. Kumar</i> and <i>S. Jenkins</i> are employees and shareholders of AstraZeneca UK Limited. At the time of the study, <i>E. Rodrigo Imedio</i>, <i>G. Mugundu</i>, and <i>J. Chmielecki</i> were employees and shareholders of AstraZeneca UK Limited. <i>E. Rodrigo Imedio</i> and <i>G. Mugundu</i> are employees and shareholders of Takeda. <i>D. Spigel</i> reports grants and/or other from Genentech/Roche, Novartis, Celgene, Bristol-Myers Squibb, AstraZeneca, Pfizer, Boehringer Ingelheim, AbbVie, Foundation Medicine, GlaxoSmithKline, Lilly, Merck, Moderna Therapeutics, Nektar, Takeda, Amgen, TRM Oncology, Precision Oncology, Evelo Therapeutics, Illumina, PharmaMar, University of Texas Southwestern Medical Center Simmons Cancer Center, G1 Therapeutics, Neon Therapeutics, Celldex, Clovis Oncology, Daiichi Sankyo, EMD Serono, Acerta Pharma, Oncogenex, Astellas Pharma, GRAIL, Transgene, Aeglea Biotherapeutics, Tesaro, Ipsen, ARMO BioSciences, Millennium, Genzyme, Intuitive Surgical, Purdue Pharma, Spectrum Pharmaceuticals, and Sysmex. <i>S. Fu</i>, <i>J.S. Rader</i>, <i>A.C. Mita</i>, <i>L. Hart</i>, and <i>S. Jones</i> declare that they have no conflicts of interest.
: The study was performed in accordance with the Declaration of Helsinki, Good Clinical Practice, applicable regulatory requirements, and the AstraZeneca policy on bioethics. The institutional review boards or independent ethics committees of all investigational sites approved the protocol, and all patients provided written, informed consent.
: Written informed consent was obtained for all patients.
: Not applicable.
: Data underlying the findings described in this article may be obtained in accordance with AstraZeneca’s data sharing policy described at ExternalRef removed. Data for studies directly listed on Vivli can be requested through Vivli at ExternalRef removed. Data for studies not listed on Vivli could be requested through Vivli at ExternalRef removed. An AstraZeneca Vivli member page is also available, outlining further details: ExternalRef removed.
: Not applicable.
: <i>TMB</i>: Resources, data curation, writing—original draft, writing—review and editing. <i>KNM</i>: Resources, data curation, writing—original draft, writing—review and editing. <i>JSR</i>: Resources, data curation, writing—original draft, writing—review and editing. <i>FS</i>: Resources, data curation, writing—original draft, writing—review and editing. <i>ACM</i>: Resources, data curation, writing—original draft, writing—review and editing. <i>JTB</i>: Resources, data curation, writing—original draft, writing—review and editing. <i>LH</i>: Resources, data curation, writing—original draft, writing—review and editing. <i>QC</i>: Resources, data curation, writing—original draft, writing—review and editing. <i>AO</i>: Resources, data curation, writing—original draft, writing—review and editing. <i>AVT</i>: Resources, data curation, writing—original draft, writing—review and editing. <i>ERI</i>: Conceptualization, supervision, methodology, project administration, writing—original draft, writing—review and editing. <i>SK</i>: Conceptualization, supervision, methodology, project administration, writing—original draft, writing—review and editing. <i>GMM</i>: Conceptualization, supervision, methodology, project administration, writing—original draft, writing—review and editing. <i>SJ</i>: Conceptualization, supervision, methodology, project administration, writing—original draft, writing—review and editing. <i>JC</i>: Conceptualization, supervision, methodology, project administration, writing—original draft, writing—review and editing. <i>SFJ</i>: Conceptualization, methodology, resources, data curation, writing—original draft, writing—review and editing. <i>DS</i>: Resources, data curation, conceptualization, methodology, writing—original draft, writing—review and editing. <i>SF</i>: Resources, data curation, writing—original draft, writing—review and editing.